Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance. We show that BET proteins are overexpresse...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:EMBO Mol Med
मुख्य लेखकों: Echevarría‐Vargas, Ileabett M, Reyes‐Uribe, Patricia I, Guterres, Adam N, Yin, Xiangfan, Kossenkov, Andrew V, Liu, Qin, Zhang, Gao, Krepler, Clemens, Cheng, Chaoran, Wei, Zhi, Somasundaram, Rajasekharan, Karakousis, Giorgos, Xu, Wei, Morrissette, Jennifer JD, Lu, Yiling, Mills, Gordon B, Sullivan, Ryan J, Benchun, Miao, Frederick, Dennie T, Boland, Genevieve, Flaherty, Keith T, Weeraratna, Ashani T, Herlyn, Meenhard, Amaravadi, Ravi, Schuchter, Lynn M, Burd, Christin E, Aplin, Andrew E, Xu, Xiaowei, Villanueva, Jessie
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2018
विषय:
Research Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5938620/
https://ncbi.nlm.nih.gov/pubmed/29650805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201708446
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन